International Kidney Cancer Symposium

home / conference / international-kidney-cancer-symposium
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute

Dr. Choueiri on the Rationale for the COSMIC-313 Trial in Advanced RCC

November 7th 2020

Toni K. Choueiri, MD, discusses the rationale for the phase 3 COSMIC-313 trial in advanced renal cell carcinoma.

Dr. Vaishampayan on the Expanding Role of TKI/Immunotherapy Combinations in mRCC

Dr. Vaishampayan on the Expanding Role of TKI/Immunotherapy Combinations in mRCC

November 6th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Chung-Han Lee, MD, PhD, of Memorial Sloan Kettering Cancer Center

Lenvatinib/Pembrolizumab Shows Promise After PD-1/PD-L1 Inhibition in Metastatic Clear Cell RCC

November 6th 2020

The combination of lenvatinib plus pembrolizumab demonstrated encouraging antitumor activity in patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy.

Brian I. Rini, MD, of Vanderbilt-Ingram Cancer Center

Dr. Rini on Choosing Between IO/IO or IO/TKI Combinations in mRCC

November 6th 2020

Brian I. Rini, MD, discusses choosing between combinations of dual immunotherapy and immunotherapy/VEGF TKIs in metastatic renal cell carcinoma.

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

Frontline Lenvatinib/Everolimus Combo Is Active in Non-Clear Cell RCC

November 6th 2020

The first-line combination of lenvatinib and everolimus elicited clinical activity in patients with advanced non-clear cell renal cell carcinoma.

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute

Cabozantinib Is Center of Emerging Treatment Approaches in Advanced RCC

November 6th 2020

Toni K. Choueiri, MD, discusses key findings from the CheckMate-9ER trial in advanced RCC, as well as ongoing trials with the potential to shift the paradigm even further.

<12